The field of "regenerative medicine" (RM) was conceptually developed to aid the body's natural capacity to self-repair, a capacity which is impaired with age and in cases of disease or injury. [1] RM is a vast and multifaceted area of medicine, often microRNA-based therapies are an advantageous strategy with applications in both regenerative medicine (RM) and cancer treatments. microRNAs (miRNAs) are an evolutionary conserved class of small RNA molecules that modulate up to one third of the human nonprotein coding genome. Thus, synthetic miRNA activators and inhibitors hold immense potential to finely balance gene expression and reestablish tissue health. Ongoing industrysponsored clinical trials inspire a new miRNA therapeutics era, but progress largely relies on the development of safe and efficient delivery systems. The emerging application of biomaterial scaffolds for this purpose offers spatiotemporal control and circumvents biological and mechanical barriers that impede successful miRNA delivery. The nascent research in scaffold-mediated miRNA therapies translates know-how learnt from studies in antitumoral and genetic disorders as well as work on plasmid (p)DNA/siRNA delivery to expand the miRNA therapies arena. In this progress report, the state of the art methods of regulating miRNAs are reviewed. Relevant miRNA delivery vectors and scaffold systems applied to-date for RM and cancer treatment applications are discussed, as well as the challenges involved in their design. Overall, this progress report demonstrates the opportunity that exists for the application of miRNA-activated scaffolds in the future of RM and cancer treatments.
with surgical connotations, which brings together Biology, Pharmacy, Materials Science and Bioengineering principles, and has emerged as a very significant field with a growing global market valued at $13.41 Billion in 2016 and estimated to reach $38.70 Billion by 2021. [2] Traditional RM approaches based on allografting and autografting are currently regarded as the gold standard procedures to repair a wide number of tissues. However, limitations such as the requirement for additional surgical procedures, limited donor tissue, donor-site morbidity, and chronic pain, the shortage in tissue/organ availability in proportion to the increased aging population, complications related to the immune system, or risk of disease transmission from donor to patient are prominent motivators for the development of new and improved RM approaches. [3] Typically, biomaterials (scaffolds), cells and external stimuli are the three major components applied in RM to provide tissue or organ grafting alternatives. [4] Scaffolds are classically introduced to provide a template for cell infiltration and tissue regeneration. Overall, these three major components can be used individually or combined, with a big research focus currently placed on different variants of biomaterial-based approaches (Figure 1) .
The growing knowledge of molecular and cellular processes underpinning tissue regeneration allows the exploration of innovative external stimuli to provide more advanced RM therapies. In addition, an emerging field very much interlinked with cancer research has started to translate the concept of biomaterial scaffolds from their typical use in RM to in vitro tools for complex microenvironment modeling; much of this vision has exciting applications in cancer research. The specific focus of this Progress Report will be on the use of biomaterial scaffolds which incorporate microRNA therapeutics as an external stimulus to enhance cell-mediated tissue repair or to serve as antitumoral treatments. Critical obstacles in the clinical translation of these technologies, including formulation chemistry and delivery methods are discussed below.
MicroRNA Biology: An Overview
miRNAs are an evolutionary conserved class of noncoding single-stranded RNA molecules naturally occurring across all biological kingdoms; in animals, the foundation member of this class of RNAs is lin-4 RNA, discovered in 1993 by Ambros and co-workers. [5] The realization that lin-4 produced two small RNAs -61 and 22 nucleotides (nt) long, which bind to the lin-14 messenger (m)RNA 3′ UTR region to repress its translation, was associated with its role in Caenorhabditis elegans larval development. [6] Followed by seminal work on the let-7 gene and homologs, we progressively gained understanding of the biogenesis and the mechanism of action of miRNAs [7] (Figure 2) . The first phase of miRNAs biogenesis consists of transcription, either directly from miRNA genes-sometimes coding for miRNA clusters-or from processed introns of proteincoding genes, rendering long primary transcripts termed primiRNAs. [8] Next, during the maturation phase in the nucleus, Drosha cleaves the pri-miRNA into a 60-70 nt stem loop precursor miRNA (pre-miRNA) with ≈2 nt 3′ overhangs, [9] which is transported to the cytoplasm by Ran-GTP and Exportin-5. [10] Once in the cytoplasm Dicer slices off the stem loop, producing an imperfect and short-lived miRNA:miRNA*duplex, [11] from which the ≈22 nt long mature single strand miRNA parts for assembly into the RNA-induced silencing complex (RISC) during the final step of the process, while the more unstable miRNA* strand typically degrades. [12] This miRNA-multiprotein complex, known as miRISC, is responsible for the mechanism of action of miRNAs, highly similar to the functionality of small interfering (si)RNA; eventually miRISC interacts, through base-pair complementarity binding, with the untranslated (UTR) region of the target mRNA. Although the 3′ UTR region is most prone, 5′ UTR regions are also capable of interacting with miRISC. [13] While perfect sequence complementarity is associated with mRNA degradation, [14] partial binding leads to translation repression and allows a multitargeting effect characteristic of miRNAs; one miRNA can silence up to 100 mRNA targets, and the mRNA coding for the production of one particular protein is susceptible to binding with a multitude of miRNAs. [15, 16] To-date up to one third of the protein-coding genome is reportedly subject to miRNA modulation, [16] and there are over 2500 human miRNAs indexed, [17] with increasing numbers of studies continuously unraveling their biological effects at an accelerated pace. Some examples of miRNA function involve (i) the regulation of developmental stages of a cell, (ii) lineage commitment, (iii) differentiation, (iv) proliferation and (v) apoptosis, as well as (vi) inflammation, immune response events and related diseases including asthma and cystic fibrosis, (vii) tumor formation, and (viii) the progression of viral infections. [18, 19] Thus, by harnessing miRNA-directed gene regulation, numerous molecular therapeutic pathways may be addressed concurrently.
Types of miRNA Therapeutics and Exogenous miRNA Regulation
In order to exploit the therapeutic potential of miRNAs, the endogenous mechanism may be modified in two opposing directions using exogenous miRNA regulators, that is, synthetic molecules which either mimic or repress the function of endogenous miRNAs. [20] Specifically, mimicking the endogenous protein expression [21] (Figure 3) . In this way, an additional benefit of miRNA therapy is the potential to respectively switch off or on gene expression as required by the intended application. Numerous synthetic variants have thus been developed to pursue miRNA therapeutics, where sequence design and chemical modifications have made a range of options available with high binding affinity, enzymatic stability and improved cellular uptake. These include: (i) hydroxyl group conjugations in the ribose 2′ position to enhance hydrophobicity, such as Exiqon's proprietary locked-nucleic acid technology (LNA) developed by Braasch and Corey, [22] (ii) functionalizations of the phosphate backbone, which introduce enzymatic resistance and have been extended to a hybrid peptide nucleic acid (PNA) variant by Fabani and co-workers, [23] or (iii) morpholino substitutions for the ribose, which also improve binding affinity (Table 1) . Modifications of the ribose ring and phosphate backbone are often combined within single nts, and significant efforts are concentrated in optimizing the balance between multiply-modified and unmodified units composing the oligonucleotides.
miRNA Mimicking
Two main strategies may be considered within the miRNA mimicking line of therapy: delivery of single or double-stranded antisense oligonucleotides known as miR-mimics, and delivery Overview of strategies applied in scaffold-based RM approaches. a) Direct implantation of cell-free scaffold (gray). b) Cells are harvested, expanded and cultured on scaffolds in vitro, then cell-seeded constructs (green) are implanted at the defect site. c) Direct implantation of cell-free scaffold bio-activated with proteins, growth factors (GFs), genes, miRNAs, or small chemical drugs (orange), for localized delivery of these external bio-stimuli to promote tissue regeneration. d) Cells are harvested, expanded in culture, combined with external bio-stimuli and cultured in vitro using scaffolds, then constructs (blue) are implanted at a defect site.
of DNA coding for miRNA precursors, generally pre-miRs ( Figure 3a) . Double-stranded miR-mimics can have up to 1000 fold higher potency than the single-stranded counterparts; this is because the additional passenger (sense) strand supports more chemical modifications, which are limited for the guide (antisense) strand in order to form the miRISC complex. [24] The alternative delivery of DNA-encoded pre-miRs is perhaps burdened by the need for nuclear access and the increased risks of miRNA biogenesis saturation, although it seems particularly appealing for long-term effects and incorporation into viral delivery vectors.
miRNA Inhibition
In the line of miRNA inhibition therapy, three different strategies are available: antisense modified oligonucleotides (AMOs)-also known as anti-miRs or antagomiRs, miRNA masks or "blockmiRs"-miRNA sponges and small molecule inhibitors such as dihydropteridine ATP analogs and some diazobenzenes [25] (Figure 3b ). AntagomiRs are the first type of miRNA inhibitors to demonstrate effectiveness in mammals; [26] they work by binding with high affinity to individual miRNAsdue to their chemical modifications-so that the interaction with the target mRNA is prevented. AntagomiRs can thus affect the multiple mRNA targets downstream of the single miRNA inhibited. Distinctively, blockmiRs are ≈15 nt antisense strands that occupy the target mRNA binding sites, again blocking the interaction with miRISC, but allowing protein translation; blockmiRs feature more predictable pharmacodynamics than antagomiRs in exchange for no ability to multitarget. miRNA sponges, often introduced as plasmid (p)DNA vectors, are long single stranded RNAs that offer yet another mechanism of action: they compete with target mRNAs for interacting with a miRNA, ultimately sequestering several miRNA copies at a time and abrogating protein silencing as a result. [27] 
Delivery of microRNA Therapeutics in Regenerative Medicine
The landscape of miRNA therapeutics has progressed at a dramatically fast pace in under 20 years, leading to the first clinical trials on liver-targeted therapies with a miR-122 inhibitor and a miR-34 mimic. [28] Such advances assert the belief in projecting this strategy to become a bench to patient bedside reality. [29] Specifically in the field of RM, pharmaceutical research and development (R&D) pipelines are currently exploring miRNAs to treat fibrosis (miR-21), inflammation (miR-155), atherosclerosis (miR-33), heart failure (miR-208), cardiac repair (miR-15) and neoangiogenesis (miR-92a). [20] The high interest of RM in the area of miRNA therapy stems from its great promise to overcome the well documented limitations of direct administration of growth factors (GF). [30] These limitations include the need for high dosing due to short half-life and poor systemic distribution, and the associated high costs. [31] In contrast, miRNA (1) Transcription of miRNA genes to primary miRNA (pri-miRNA) is followed by (2) loop-processing by the Drosha/DGCR8 complex; this generates a precursor (pre)-miRNA that is then (3) transported into the cytoplasm by Exportin-5/Ran-GTP. (4) Dicer/ TRBP cleaves the hairpin releasing the miRNA:miRNA * duplex. (5) The mature miRNA separates to form the miRISC complex with the Argonaute (AGO) protein core, while the miRNA * strand degrades. (6) Target mRNAs interact with miRISC complexes, leading to (7) mRNA degradation or translational repression amongst other complex regulatory functions.
therapy offers the ability to transiently regulate cellular protein production at low doses, featuring an extended half-life over GF and pDNA: the cytoplasmic half-life of numerous miRNAs spans from over 24h to several days [32] while the maximum documented for pDNA is 5h. [33] However, the delivery of naked miRNA has demonstrated limited success, and the development of safe and efficient delivery systems is widely regarded as the critical progress-limiting factor; [34] in fact, 25% of the US miRNA therapeutics patents relate to RM applications, while R&D in miRNA delivery systems is responsible for ≈30% of that share. [35, 36] miRNA delivery systems for RM purposes generally combine delivery vectors and 3D biomaterial scaffolds in order to achieve efficiently sustained therapeutic effects in a localized manner. The characteristics and functions of both components, detailed below, generally translate across pDNA, siRNA, and miRNA delivery systems.
Vectors for microRNA Delivery
A range of vectors, typically classified as viral or nonviral, may be employed to aid cellular entry of miRNAs and subsequently facilitate their transport from the lysosomes into the cell cytoplasm, hence preventing the phenomenon of lysosomal degradation. [37, 38] The numerous options available within both categories have been reviewed extensively in recent publications, [39, 40] yet there is still no consensus in an optimal system. [38] This section focuses on miRNA delivery vectors which have been considered for the development of scaffold-based miRNA delivery systems, their design and characteristics.
Viral Vectors
By their very nature, viruses are excellent at gaining cellular and nuclear entry; they characteristically achieve high transfection levels and thus are at the forefront of the clinical advances in the broad field of gene therapy. This includes their use in 67% of registered gene therapy clinical trials, [41] and in the market-approved GlaxoSmithKline's Strimvelis and MolMed's Zalmoxis treatments. [42] Viral miRNA delivery may serve to stably modify endogenous miRNA expression; a valuable goal to treat chronic degenerative diseases within the RM arena, such as osteoarthritis. Among the distinct classes, retroviruses are highly efficient at entering dividing cells, while lentiviruses, adenoviruses (ADV), and adeno-associated viruses (AAV) can enter both dividing and nondividing cells. [43] Retroviral vectors are associated with high risks of genome integration at undesired locations, an often fatal sideeffect known as insertional mutagenesis. In comparison with retroviruses, lesser insertional mutagenesis risks are reported with the use of lentiviruses, [44] thus perhaps encouraging recent developments with lentiviral engineering of cells prior to seeding onto biomaterial scaffolds. [45] [46] [47] ADVs and AAVs delivering miRNAs are less explored in biomaterial-based RM approaches, although their use in traditional in vitro transductions with miRNA-expressing cassettes has been discussed in other reviews. [48] AAVs may shortly garner more attention in the field: their characteristic small size, their lack of pathogenicity in humans and their reduced immunogenicity in comparison with ADVs places them in the spotlight of forthcoming research in miRNA delivery. [43] Baculoviruses (BV) are similarly nonpathogenic to humans (they target insects naturally), with the additional safety advantages of not undergoing chromosomal integration or replication in mammalian cells. BVs are gradually garnering attention as miRNA delivery vectors, [49] with a panel of osteogenic miRNAs screened for therapeutic effects in vitro, and reported beneficial bone healing effects when assessed as a cotreatment with bone morphogenetic protein-2 (BMP2) in a nude mice calvarial defect model. [50] Many disadvantages continue to surround the use of viral vectors however including immunogenicity and biodistribution concerns, high production costs and complexity for high-mass production. A nascent alternative are virus-like particles (VLPs), a recombinant version of viral capsids recently explored to deliver miRNAs for the treatment of systemic lupus erythematosus. [34, 51] VLPs resemble the cell tropism and natural intracellular trafficking capacities of the virus while being noninfectious, and thus hold significant promise for the clinical advancement of the field in the coming years.
Nonviral Vectors
Typically, nonviral vectors allow the transfer of large cargoes with varying efficiencies depending on the cell type targeted, and result in temporary transfection effects. [38, 39, 52] This temporality can be advantageous for numerous RM applications, where time-span limit of the therapeutic is of utmost importance, and a maintained effect after tissue regeneration may be highly detrimental. Additionally, high-mass production of nonviral methodologies tends to be less complex and costly than that of viral vectors. [52] Several cationic polymers are commercially exploited for miRNA delivery at a research level, while innovations in the nanotechnology arena increasingly continue to introduce interesting alternatives. Cationic lipids are among the most commonly utilized nonviral vectors for gene therapy applications. The use of commercial cationic lipids in biomaterial-based approaches to deliver miRNA therapeutics is exemplified by the widespread use of Lipofectamine 2000 [53] [54] [55] [56] along with Lipofectamine RNAiMAX [57] and SiPORT NeoFx. [58] Generally, cationic lipids complex with the miRNA cassettes through electrostatic interaction, and the overall positive charge of the complex dictates the cellular uptake, although neutrally charged liposomes can also encapsulate the cargo within their core. Complexes formed by encapsulation of the miRNA cargo, as opposed to charge adsorption, are not limited to lipid-based vectors and have also shown effective delivery profiles in RM applications. The structural versatility of lipid-based vectors is of key value for adapting their use to different cargos as well as to target distinct cell types. [59] However, this is counterbalanced by their reported cytotoxic and proinflammatory effects, some of which have been associated with their ability to trigger the generation of intracellular vacuoles. [60] Polyethyleneimine (PEI) derivatives have also been extensively studied as miRNA delivery systems, [19, 61, 62] and specifically PEI-poly(ethylene glycol) (PEG) nanoparticles (NP) have recently demonstrated interesting profiles when encapsulated within poly(lactic-co-glycolic acid) (PLGA) microspheres in a poly(l-lactic acid) (PLLA) scaffold [63] or as part of a calcium chloride cross-linked alginate hydrogel system. [64] PEI is watersoluble and easily attracts negatively charged ions to aid the polyplex cargo escape the endolysosomal compartment in what is known as "the proton sponge effect." [65] The extent of this effect is dependent on a parameter termed N/P ratio, that is, the proportion of moles of nitrogen in PEI to moles of phosphate in the cargo. While elucidating the optimal N/P ratio for a target cell type can render PEI a remarkably efficient miRNA delivery vector, evidence of significant cell damage derived from their use remains a considerable drawback in terms of clinical application. [66] Poly(β-amino esters) (PβAE) are yet another class of polymers with negligible cytotoxicity and amenable to gene delivery via the proton sponge effect in a range of cell types, including hMSCs, hADSCs, human embryonic stem cellderived cells (hESCds), macrophages, HEK-293, U-87 MG and lung cancer cells. [67] [68] [69] Interestingly, PβAEs have demonstrated 30-60% transfection efficiency when delivering pDNA, [68] and up to 70% silencing following siRNA delivery, [70] with one study also assessing short hairpin (sh)RNA delivery. [69] Despite the tunability of these materials, which may specifically allow for kinetically controlled biodegradation, [71] PβAEs have yet to be explored as miRNA carriers in scaffold-based delivery platforms.
A diblock copolymer made of dimethylaminoethyl methacrylate has also shown promise for the delivery of siRNA in hydrogel-based systems. These nanoparticles have demonstrated significant siRNA delivery and gene knockdown in a number of studies, which is accredited to the ability of these NPs to protect and allow sufficient cytosolic accumulation of siRNA. [72] While they have also been used when combined with polylactic acid (PLA) PLA forming amphiphilic starshaped polymers to deliver miRNA-21 and doxorubicin to treat glioma, [73] as of yet, they have not been used to deliver miRNA on scaffold-based platforms but appear to hold great potential for such applications.
Other nonviral synthetic vectors that generally feature low cytotoxicity have garnered significant attention in pDNA and siRNA delivery, such as dendrimers, [40] cyclodextrins, [74, 75] and cell penetrating peptides (CPP). [76, 77] However, all of these are to-date minimally explored in RM applications of miRNA therapeutics. Of relevance, polyamidoamine (PAMAM) dendrimers were recently applied to a dextran-based hydrogel to deliver miR-205 mimics and antagomiR-221 for breast cancer treatment applications. [78] This work demonstrated a macropinocytosis-mediated uptake mechanism for the dendrimer-miRNA complexes, with substantially improved efficiency in comparison to the original PAMAM formulations reported. [79] Similarly, cyclodextrins undergo unspecific (clathrin independent) uptake [80] but also serve to improve water-solubility and biodistribution of the cargo due to their cyclic oligosaccharide nature. [81] In the case of CPPs, uptake may occur either through transitory micelle formation, endocytosis in its four variants, or direct penetration driven by penetratin or TAT (GRKKR-RQRRR) domains, [82] which explains their documented high transfection efficiencies. [76] Overall, dendrimers, cyclodextrins, and CPPs offer extensive versatility in their structure and associated phys-chem properties, ultimately allowing the formation of the complexes to occur through charge adsorption or physical encapsulation; research in adapting and optimizing these vectors for miRNA delivery will undoubtedly impact the application of miRNA therapeutics in RM.
Natural derived nonviral vectors are also being increasingly considered for miRNA-RM therapeutics due to their high biocompatibility features: chitosan, exosomes, and inorganic NPs belong to this category. Chitosan is a cationic polysaccharide first introduced to gene delivery in the late 1990s [83] that can be adapted to different nucleic acid cargoes by modifying the chain architecture and/or the acetylation and polymerization degree. [84] Thus, while 80% deacetylated chitosan showed low efficiencies transfecting pDNA, fully deacetylated chitosan demonstrated remarkable functionality of the eluted siRNA along a 5 d time-course in a human lung carcinoma cell line (H1299). [84] More recently, shortening the chain length has provided improved efficiencies (≈45%) in the transfection of rat mesenchymal stem cells with pDNA, [85] and similarly, highly depolymerized chitosan delivering miR-145 to human breast adenocarcinoma (MCF-7) cells achieved ≈50% target silencing. [86] Exosomes play a critical role in paracrine signaling and intercellular miRNA trafficking guided by the tissue-specific proteins found on their surface. [87] Early reports have linked exosomes, and their miRNA content, with several tissue regeneration processes, such aspects could be soon recapitulated in RM approaches to deliver exogenous miRNA modulators, [88] and their assessment for this purpose has indeed begun to focus on siRNA delivery. [89] Several types of inorganic NPs based on gold, silver, iron, and calcium phosphates (CaP) offer innovative aspects in the journey toward commercially applicable nonviral miRNA delivery vectors. Cysteamine-Au-PEG NPs optimized for miRNA reporters across neuroblastoma and ovarian cancer cell lines built on the beneficial amphipilicity and surface area of these materials. [90] Qureshi et al. developed an interesting photocleavable-Ag nanoparticle system, which showed improved delivery of miR-148b mimic to human adipose-derived stem cells (hASCs) over the commercial transfection reagent TurboFect; [91] the preclinical in vivo evaluation of a therapeutic incorporating this system onto Matrigel and polycaprolactone (PCL) scaffolds is described in further detail in Section 5.1. [92] Fe 3 O 4 paramagnetic NPs were skillfully combined with PEI to deliver miR-335 to human mesenchymal stem cells (MSC), with intended application in the treatment of cardiovascular diseases, in work carried out by Schade et al. [62] The range of 80% uptake efficiency reported in this work was in exchange for acceptable dead cell levels -below 20%, with the added possibility of magnet-controlled tissue targeting following administration of this potential therapeutic system. CaPs are an often overlooked option in gene therapy, disregarded for their traditionally low transfection efficiencies delivering pDNA and their instability in solution. [93] However, research carried out by our lab has optimized CaPs for this purpose, using a formulation of the hydroxyapatite mineral phase as nonaggregating nanoparticles (nHA) previously developed in-house. [94] These NPs were originally investigated to develop a collagen-nHA composite scaffold with improved mechanical properties; [94] this material was then adapted to surpass the pDNA transfection efficiency of a commercial CaP transfection kit in hMSCs, [95] and was further tailored to deliver both reporter miR-mimics and antagomiRs to the same cell type, with a single low dose maintaining a silencing efficiency of greater than 90% over 1 week. [96] Although little is known regarding the uptake mechanisms of CaP-nucleic acid complexes, their ability to form precipitates on the cell surface and undergo clathrin and dynamin-dependent endocytosis has been documented, [37] and their pH-dependent solubility allows complex dissociation to commence within intracellular compartments. [97] Considering the ease of production, cost effectiveness and high biocompatibility of CaPs, [98] together with the newly improved efficiency of these nHA particles to deliver miRNA therapeutics, the proposed system has demonstrated a substantial potential for the derivation of new therapeutics in this field.
Scaffolds for microRNA Delivery
In the late 1990s, the idea of "gene-activated matrixes" emerged; the first report documented collagen-based scaffolds delivering β-galactosidase pDNA to significantly promote bone formation. [99, 100] This concept has now more recently also been translated to miRNA delivery. The primary role of 3D biomaterial scaffolds is to act as templates for cell attachment and tissue repair; however their use to locally deliver therapeutics has become increasingly appealing to target a specific tissue more safely. [36, 101] The scaffolds 3D microenvironment can provide physical protection from degradation and prevent the rapid clearance of small complexes from the target site; without this protection, the effective action time-frames may be too short to achieve therapeutic efficacy. [102] Thus, it is becoming well-established that the combination of the aforementioned miRNA delivery vectors together with biomaterial scaffolds will prolong the time-frames of localized delivery, [99, 103, 104] a favorable prospect for RM applications. Of note, functional differences have been reported across monolayer and scaffold transfection experiments, being a testament to the effect of the 3D microenvironment. Thus the necessity to carry out thorough in vitro characterization of the scaffold-based miRNA therapeutic system should not be overlooked.
Scaffolds can facilitate "cell-free" or "cell-mediated" miRNA delivery, also termed in situ or ex situ delivery, respectively (Figure 4) . In situ transfection indicates that miRNAs exist within the scaffold structure prior to the addition of cells; these scaffolds are implanted "cell-free" in the tissue void, where they will interact with the resident and homing cells to regenerate such defects. [105] The scaffold acts as a depot for the complexes and then infiltrating cells establish contact with these along the structure of the scaffolds to internalize them and become transfected. On the contrary, ex situ transfection consists in first administering the miRNA treatment to a controlled cell population, which is then mixed with or seeded onto the relevant scaffold. This second strategy may require an additional period of in vitro culture before implantation in the defect site; ultimately this cell population is the only one modified by the miRNA treatment and thus responsible for the therapeutic outcome upon implantation. At present, in situ miRNA delivery systems remain undeveloped in comparison with pDNA-activated scaffolds, and ex situ miRNA delivery counts for a higher number of reports. [102, 106] Whether one of the routes may be better suited for clinical translation remains to be elucidated, although in situ transfecting scaffolds hold greater potential to exist as "off-the-shelf" products. [107] Many distinct scaffold types have been tuned to serve the purpose of miRNA delivery, including several hydrogels, [58, 92, 106, [108] [109] [110] [111] [112] [113] [114] electrospun fibers, [63, [115] [116] [117] [118] and more prolifically porous or spongy scaffolds. [46, 47, 50, 54, 55, 96, 112, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] Before reviewing the details of their applications, summarized in Table 2 and described further in the next section, we will discuss the key characteristics making these materials amenable to miRNA delivery. First very general qualities must be fulfilled: biocompatibility, bioresorbability and ease of fabrication. [103] Additionally, ease of sterilization, stability and long-term storage, are highly important from the perspective of clinical applicability. [131] High porosity, tissue anastomosis and mechanical strength are relevant aspects for orthopedic applications; however, favorable rheological properties, including responsiveness to different physical stimuli and a good viscoelastic component are the main factors to optimize in the case of hydrogel formulations. [132] Overall, the scaffold architecture must allow the ingrowth of neovascularization for the successful application of nearly every biomaterial in RM, and recently, the impact of material nanotopography is also gaining recognition. [133] In order to specifically adapt any scaffold to miRNA delivery, the material must retain the miRNA complexes while facilitating their sufficient exposure to the infiltrating cells. [134] Reciprocally, the presence of miRNA Enhanced expression of PGC-1a, and contractile force 2 weeks myotubes culture [111] Muscle complexes in the scaffold structure must not negatively affect its mechanical and structural features or deter cellular retention and attachment to the scaffold. [135] Depending on the nature of their components, biomaterials are typically classified as synthetic, natural, ceramics, or composites, that is, combinations of these. Certain materials are more applicable for a fabrication technique or a type of formulation. For example, PEG is a synthetic polymer frequently employed in the preparation of hydrogels, such as the commercial HyStem-HP utilized by Li et al. to deliver miR-26a mimics, [58] or the PEG-norbornene system for human bone marrow derived (BM)-MSCs nucleofected with a dual miR-148b mimic + miR-489 inhibitor combination. [106] An in situ forming PEG-hydrogel has also been the supporting biomaterial of an UV-triggered "on-demand" miR-20a release system. [136, 137] A rare synthetic polymer for RM applications, pluronic, has recently aided the in vivo lentiviral delivery of miR-26a mimics for cardiovascular applications; [114] this is an amphiphilic triblock copolymer that self-assembles in situ producing a micellated gel. Characteristically, synthetic polymers offer extensive possibilities to tailor their mechanical properties and degradation rates by altering chain lengths, as well as proportions of the mixture components. Although several of these materials hold Food and Drug Administration approval for RM purposes, in the case of synthetic polymers biodegradable through esterhydrolysis, their acidic degradation by-products can exert an inhibitory effect on tissue formation. [138] To diminish these undesired effects, it is frequently combined with natural polymers such as hyaluronic acid (HyA), as in the commercial HyStem-HP and Glycosan HyStem. Other natural polymers included in miRNA eluting hydrogels are alginate, [112] silk fibrin, [111] fibrinogen, thrombin, and Matrigel. [92, 110] Of note, hydrogels are the first biomaterials used successfully for the delivery of naked miRNA therapeutics, [106, 108, 109] that is, without the addition of a delivery vector. While this strategy simplifies the fabrication of the final miRNA-activated scaffolds, it may also accelerate the release of the cargo, leading to undesired bolus effects.
Electrospinning is a distinct fabrication method that produces nanofibrous scaffolds typically using material sources such as gelatin, [115] synthetic PLLA, [63] PCL, [92, 117] or PEG-PCL copolymers. [116] Interestingly, most of the nonviral, nonlipid vectors tested for 3D-miRNA delivery have utilized biomaterials fabricated using this method: Qureshi's photocleavable silver NPs, [92] the commercial Transit-TKO transfection reagent, [115, 117, 139] an innovative peptic sequence REDV-trimethyl chitosan-PEG complex, [116] and hyperbranched (HP) PEI-PEG polyplexes. [63] Moreover, with the exception of the Ag-NPs, all the remaining systems have been developed as in situ "cell-free" miRNA transfecting platforms, underscoring great clinical potential and versatility of this fabrication method. Finally, spongy porous scaffolds account for the largest evidence in miRNA delivery: 50% of these are ceramic-based or ceramic-composite materials, the other half is represented by a mix of compositions. Ceramics are inorganic crystalline structures with characteristically high melting points, hardness and brittleness, among which CaPs have been widely studied. CaPs exist in forms of different stoichiometric proportion of calcium to phosphate; this includes brushite, tricalcium phosphate (TCP), and hydroxyapatite (HA), the mineral component found in teeth and bone. [140] β-TCP scaffolds were used by Deng et al. in preclinical studies of lentiviral miR-31 inhibition, [45, 120] and HA/TCP scaffolds were utilized, in combination with Lipofectamine 2000, by Eskildsen et al. to deliver miR-138 inhibitors in vitro, [54] and more recently by Wang and co-workers to deliver miR-26a mimics in vivo. [55] Similarly, nHA/PCL and carboxy-methyl-cellulose/zinc-doped nHA composite scaffolds have been combined with Lipofectamine 2000 and X-treme Gene transfection reagent respectively. [56, 125] The common denominator of this body of work is the minimal intervention of the scaffold in the delivery of the miRNA, as the cells are transfected ex situ prior to scaffold seeding. Notably, in the work carried out in our lab by Mencía Castaño et al. the porous collagen-nHA scaffolds take active part in the in situ delivery of both miR-mimics and antagomiRs to hMSCs. [96, 124] These reports demonstrate the differences between the 3D miRNA-activated system in comparison to monolayer: in the in situ transfection the scaffold retains the miRNAs within its 3D structure, relatively limiting the exposed surface area of the complexes to the infiltrating cells while prolonging the onsite presence of these complexes. Taken together, significant research has explored the miRNA delivery potential of a wide range of material types and fabrication methods in combination with either viral or nonviral delivery vectors. Although the field of scaffold-based miRNA delivery is nowadays at a nascent juncture, these reports reflect the vast landscape of options available to derivate advanced materials tailored to the specific needs of each particular RM application, whose therapeutic potential is illustrated in the next section.
MicroRNA-Scaffold Based Therapies for Tissue Repair
The vast potential of miRNA therapies for tissue repair and RM has been extensively reviewed in the last few years in either general terms [25, 141] or with more focused applications in mind such as bone/orthopedics, [104, 142] angiogenesis, [143] the cardiovascular system, [144] or skin, [145] but the area of scaffold-based miRNA delivery in RM is still relatively in its infancy. To date, reports on scaffold-mediated miRNA delivery have focused more on specific areas of regenerative medicine including osteogenesis and bone repair as well as the cardiovascular arena (Table 2 ), but this progress report aims to give a broader overview encompassing a variety of areas of RM.
Osteogenesis and Bone Repair
The majority of available reports for scaffold-based miRNA delivery in the osteogenesis and bone repair field focus on the application of miRNA 26a. [58, 63, 146] Li et al. [58] documented the first report in 2013 using BM-MSCs, HyStem-HP hydrogel, and miR-26a mimic. They demonstrated almost full repair of the defect 12 weeks postimplantation and significantly enhanced vascularization confirming that miR-26a had the capacity to regulate endogenous angiogenic-osteogenic coupling for enhanced bone regeneration. Wang et al. [146] employed an alternative approach with ASCs, miR-26a mimic and Lipofectamine 2000 on porous HA scaffolds. Following 12 weeks implantation, histological assessment showed markedly enhanced bone formation. The final and most eloquent report went a few steps further and delivered HP-PEI-miR-26a polyplexes on a nanofibrous PLLA scaffold without an external cell source in contrast to the earlier reports [58, 146] and of great importance, mechanistically identified the bone regeneration target gene for miR-26a for the first time. [63] To further support the spatiotemporal release of the miRNA, the miRNA-loaded polyplexes were also encapsulated in biodegradable PLGA microspheres which were then immobilized onto the scaffolds. Importantly, these two-stage, cell-free, miR-26a loaded scaffolds demonstrated significantly enhanced bone regeneration in critical-sized calvarial bone defects in both healthy and osteoporotic mice after only 8 weeks. miR-26a has previously been shown to regulate suppression of connective tissue growth factor, [147] angiogenesisthrough bone morphogenetic protein 2 (BMP2)/drosophila mothers against decapentaplegic protein (SMAD) signaling -in endothelial cells, [148] and atherosclerosis via a EphA2/p38 MAPK/vascular endothelial growth factor (VEGF) pathway. [149] Work by Luzi et al. [150] has however pointed at a complex role for the miR-26a::SMAD1 match in human ASCs osteogenesis. Finally, Zhang et al. [63] importantly demonstrated that miR-26a regulates osteoblast function through targeting glycogen synthase kinase-3beta (GSK-3beta), a gene known to improve bone mass and increase the mineral apposition rate and bone mineral density (BMD) when inhibited in OVX mice. [151] Deng et al. [46, 120, 121] have focused on the assessment of scaffold-mediated miR-31 delivery in various different cells, scaffolds and defect models. Their first study on the evaluation of ASCs combined with lentivirus-miR-31 loaded β-TCP scaffolds [120] showed that miR-31-knockdown ASCs significantly improved bone regeneration in vivo. This work highlighted a Runx2/Satb2/miR-31 regulatory loop activated by BMP to play a vital function in ASC osteogenesis and bone regeneration. Having previously reported that knockdown of endogenous miR-31 in vitro significantly improved the osteogenic capacity of BM-MSCs, [152] the group went on to assess the therapeutic potential of lentivirus-miR-31-modified BM-MSCs cultured on poly(glycerol sebacate) scaffolds. [46] Results demonstrated that miR-31 inhibition could successfully enhance bone repair in the defect area. Their final miR-31-based study assessed the role of lentivirus-miR-31-inhibitor modified BM-MSCs seeded on β-TCP scaffolds in repairing orbital bone defects in a canine model for 16 weeks. [121] The results of this study confirmed their previous reports with downregulation of miR-31 demonstrating a significant role in osteogenesis and bone regeneration. miR-148b mimic has also been highlighted in a number of scaffold-based studies. Mariner et al. [123] first described its application in combination with miR-489 inhibitor to accelerate in vitro osteogenic differentiation of BM-MSCs. Cells were transfected to coexpress both the mimic and inhibitor using nucleofection before being photoencapsulated on PEG-norbornene scaffolds. Results showed a significant enhancement of alkaline phosphatase (ALP) activity, calcium deposition and osteogenic gene expression. An alternative method involving ASCs transduced with BVs for codelivery of BMP2 pDNA and miR148b on a gelatin-coated PLGA scaffold was investigated to determine the effect on osteogenic differentiation. [153] The BV hybrid used, composed of flippase recombinase (FLPo) and Frtflanking cassette, has previously shown to substantially prolong transgene expression. [122] Having assessed the osteogenic effect of a number of miRNAs in vitro, miR-148b was chosen as the frontrunner and demonstrated enhanced in vitro osteogenesis when cotransduced with BMP2. Scaffolds containing ASCs coexpressing BMP-2/miR-148b were implanted into criticalsize mouse calvarial bone defects and showed accelerated bone healing and remodeling after 12 weeks, filling ≈94% of the bone defect area and ≈89% of the bone defect volume. Following on from this study, Li et al. [154] focused on elucidation of the molecular target for 148b as it had not been previously identified. This study revealed miR-148b directly targets NOG, which negatively regulates BMP2-induced osteogenesis and bone formation. The authors recapitulated the codelivery of BMP2 and miR-148b [153] utilizing an alternative Cre/loxP-based BV vector for stronger transgene expression and reduced cytotoxicity, [122] in an attempt to improve the calvarial bone healing. These scaffolds demonstrated superior bone regeneration and restoration of the bone density to 89% of the original, indicating the potential of this alternative scaffold system. Qureshi et al. [92] also assessed miR148b delivery from scaffolds for enhanced bone repair. Photocrosslinked-miR-148b was conjugated to silver NPs (PC-miR148b-SNP) to allow for greater temporal control and improve bone repair of a critical-sized mouse calvarial defect. PC-miR148b-SNP conjugates combined with ASCs were loaded on PCL scaffolds and efficiently regulated ASC osteogenic differentiation and improved calvarial defect closure by ≈32%. Ultimately the results demonstrated the translational potential of the photoactivated miRNA delivery system to enhance ASC osteogenic differentiation.
Recent work from our Tissue Engineering Research Group (TERG) in Dublin has concentrated on nHA particle-based delivery of miR-mimics and miR-inhibitors from porous collagen-nHA scaffolds paying particular attention to bone repair. [96, 124] Studies on scaffold-based gene delivery in the lab originally began with the delivery of pDNA including BMP2 [95] and combinations of BMP2 and VEGF [155] utilizing the nHA particles [94] and coll-nHA scaffolds [94, 156] developed in-house specifically for bone repair. Having demonstrated the dramatically enhanced therapeutic potential of such systems not only for bone but also cartilage and nerve repair, we also progressed to investigating the utility of alternative gene delivery vectors including PEI, [85, 155, 157] chitosan, [40, 158] Lipofectamine 2000, [75] and cyclodextrin, [75, 159] different genetic cargo such as pDNA, [85, 95, 155, 157] miRNA, [96, 124] and siRNA, [75, 159] and various scaffold types including collagen alone, [85, 95] collagennHA, [75, 95, 96, 124, 155, 159] collagen-HA [85] and collagen hyaluronic acid (coll-HyA) [85] to tailor our systems depending on the final application required. [158] Delivery of the miR-mimics and miR-inhibitors from porous collagen-nHA scaffolds yielded very promising results demonstrating silencing functionality of ≈20% and 88.4%, respectively. The antagomiR-functionality levels achieved in our "coll-nHA-nanomiR" system were improved over miR-mimic silencing, although 20% silencing can still trigger therapeutic improvements in vivo, [108] providing evidence suggestive of the potential benefit of the TERG system. A more recent study functionalized the collagen-nHA scaffolds with miR-133a inhibitor, delivered using nonviral nHA particles, to enhance hMSC osteogenesis, building on the validated direct targeting of miR-133a-(3p) over Runx2, a master transcription factor of osteogenesis. [160] Results comprehensively demonstrated increased gene expression of Runx2 and osteocalcin, in addition to enhanced alkaline phosphatase activity and calcium deposition, showing improved therapeutic potential of the scaffold previously optimized for bone repair applications ( Figure 5) . In vivo assessment of this system (data not yet published) has further demonstrated the benefits of the application of these coll-nHA-nanomiR scaffolds.
The Alsberg lab has recently focused their attention on the effect of miR-20a to guide enhanced stem cell osteogenesis. [136, 137] Nguyen et al. [137] developed in situ forming PEG hydrogels for controlled, localized and sustained delivery of siRNA (siNoggin) and miR-20a, complexed to PEI, to BM-MSCs. Extended delivery of siNoggin cotransfected with miR-20a from this polymeric scaffold allowed enhanced osteogenic differentiation of encapsulated stem cells and extended regulation of cell behavior. Following on from this study, Huynh et al. [136] developed the first on demand dual-crosslinked in situ forming photodegradable PEG-based hydrogel to actively control the release of unmodified/chemically modified siNoggin or miR-20a complexed to PEI via UV irradiation to induce the enhanced osteogenic differentiation of BM-MSCs. This study presents an ideal system for "on-demand" release of genetic materials via external UV application that holds promise for tissue regeneration.
Gelatin nanofibers have been used for the localized transient delivery of miR-29a inhibitor to increase extracellular matrix (ECM) deposition as the miR-29 family are known to negatively regulate ECM synthesis, targeting collagens, and osteonectin/ SPARC. [115] miR-29a inhibitor, complexed with TKO transfection agent, and loaded on these electrospun gelatin nanofibers demonstrated continuous release of miR-29a inhibitor while cultured MC3T3-E1 cells produced more osteonectin, among other markers. BMSCs from transgenic pOBCol3.6 cyan reporter mice, grown on nanofibers loaded with miR-29a inhibitor also showed elevated Col3.6 cyan expression demonstrating successful transfection and enhanced collagen production. Lentivirus has been used to deliver miR-135 to ASCs for assessment of osteogenesis and bone repair in vitro and in vivo. [47] For in vivo assessment, transduced ASCs were combined with poly(sebacoyl diglyceride) (PSeD) scaffolds and implanted in critical-sized rat calvarial defects. Results correlated with in vitro assessment and showed that miR-135 mimic treatment resulted in significant new bone formation with elevated BMD, increased trabeculae number (Tb.N) and enhanced mineralization staining. In contrast, miR-135 inhibitor treatment attenuated these processes suggesting that miR-135 positively regulates in vitro and in vivo ASC osteogenesis and bone regeneration.
Lipofectamine 2000-miR-221-inhibitor transfected ASCs seeded on a nHA/PCL scaffold has also been assessed for osteogenic enhancement. [56] This in vitro study demonstrated significantly enhanced Runx2, osteocalcin and ALP activity. Interestingly, although gene expression demonstrated significantly enhanced Runx2 and osteocalcin on miR-221-inhibitor transfected ASCs in monolayer, no significance was obtained in ALP activity compared to control ASCs in osteogenic media. miR-15b has been tested in combination with a carboxymethyl cellulose-nHA based scaffold to determine its effect on osteogenic differentiation using mouse(m) MSCs transfected with miRNA-15b using X-treme Gene transfection reagent. [125] Individually, media from the scaffold and miR-15b treated mMSCs were able to promote osteoblast differentiation and when these treatments were combined there was an additive effect on promotion of osteoblast differentiation showing that this system may harbor some utility for increasing mMSC osteogenesis in vitro. miR-2861 has been shown to be increase the osteogenic commitment of human periodontal ligament stem cells (hPDLSCs) grown on a 3D scaffold and demonstrated the successful overexpression of miR-2861 and RUNX2 in hPDLSCs cultured in presence of the scaffold under osteogenic and standard conditions. [126] Xie et al. [127] showed that miR-146a negatively regulates osteogenesis and bone regeneration of ASCs both in vitro and in vivo. Overexpressing miR-146a using lentivirus suppressed ASC osteogenesis while inhibition of miR-146a greatly promoted this process in vitro, corresponding with modulation of miR-146a's direct target, SMAD4, an important coactivator in the BMP signaling pathway. Lentivirus-miR-146a mimic/ inhibitor transduced ASCs were then combined with PSeD scaffolds and implanted in critical-sized rat cranial defects. Treatment with miR-146a inhibitor greatly enhanced ASC-mediated bone regeneration with higher expression levels of SMAD4, Runx2, and Osterix detected in newly formed bone, thus outlining the important role for miR-146 in bone regeneration.
Lentiviral-based miR-125b down regulation has demonstrated an important role in the process of BMSC osteogenic differentiation and in vivo bone repair by targeting bone morphogenetic protein type 1b receptor (BMPR1b). [128] Demineralized bone matrices (DBMs) preseeded with the miR-125b inhibitor transduced BMSCs displayed improved repair capacity of the defects. This was highlighted by an increase in BMD by 51%, an increase in Tb.N by 79% and enhanced histological staining for new bone generation and bone maturity. Having demonstrated the inhibition of miR-222 promoted osteogenic and chondrogenic differentiation in vitro, miR-222 has been mixed with atelocollagen and administered in a rat refractory fracture model for in vivo bone healing assessment. [113] Bone union at the fracture site and enhanced capillary density was achieved in miR-222 inhibitor treated groups 8 weeks postimplantation. Overall, this study successfully demonstrated the effect of miR-222 knockdown on acceleration of bone healing by enhancing osteogenesis, chondrogenesis, and angiogenesis. Osteoporotic bone defects have also been healed by BV-engineered OVX-BM-MSCs expressing miRNA sponges carrying miR-214 either alone or in combination with BMP2. [130] This assessment was carried out by implanting gelatin Spongostan scaffolds preseeded with transduced OVX-BM-MSCs. Coexpression of BMP2 plasmid and miR-214 sponges in OVX-BM-MSCs enhanced synergistic healing. These results present a new approach for osteoporotic bone defect treatment.
Cartilage Repair
There remains a major unmet clinical need for the development of repair strategies for damaged cartilage. Even repair of Adv. Healthcare Mater. 2018, 7, 1700695 Figure 5 . NanoantagomiR-133a(-3p) loaded scaffolds demonstrate enhanced hMSC osteogenesis. a,b) Runx2 and ALP mRNA expression was upregulated in the nanoantagomiR-133a-3p loaded scaffolds at day 3 and 7, respectively. Mean + standard deviation, n ≥ 4, *p < 0.05. c) Calcium content was increased by day 14 and maintained after 28 d compared to the control groups. Mean + standard deviation, n = 3, **p < 0.001, #p < 0.001 compared to all other groups. d) Alizarin red staining demonstrated calcium deposits and e) OCN immunofluorescence staining (green; blue = DAPI stained nuclei) showed increased protein expression in the nanoantagomiR-133a loaded scaffolds after 14 and 28 d, scale bar = 50 µm. Adapted with permission. [124] Copyright 2016, the authors. Published under CC-BY 4.0 license. small cartilage defects is hampered for reasons including the avascular composition of cartilage tissue, low cell density and slow diffusion of nutrients among others, but it is believed that development of tissue-engineered RM strategies comprised of a cell source such as MSCs, a biomaterial scaffold/hydrogel and external signals such as the inclusion of GFs/genes/miRNAs may hold particular promise. While substantial efforts elucidating miRNAs involved in cartilage development, disease and repair have been reported to-date, perhaps surprisingly there has only been one report describing scaffold-based miRNA delivery; thus cartilage miRNA research is still very much in its infancy.
Lolli et al. [112] recently published a body of work showing silencing of antichondrogenic miR-221 in hMSCs promotes cartilage repair in vivo. This group previously demonstrated that silencing of the antichondrogenic regulator miR-221 resulted in enhanced chondrogenic marker expression in monolayer BM-MSCs cultured without TGF-β. [159] This study was validated here both in pellet culture and additionally in vivo. [161] This study was validated here both in 3D pellet culture and additionally in vivo. [112] Lipofectamine RNAiMAXmiR-221 inhibitor was used to transfect monolayer BM-MSCs and showed higher than 95% miR-221 knockdown before resuspension in alginate. This alginate-cell suspension was then added to simulated osteochondral defects and implanted subcutaneously in nude mice. miR-221 inhibition significantly promoted in vivo cartilage repair after 12 weeks and deposition of the hypertrophic marker, collagen type X, was completely absent. This study opens new possibilities for the use of scaffold-based miRNA delivery in cartilage tissue engineering.
Muscle Repair
In order to use 3D engineered human skeletal muscle tissue for translational studies to treat muscular diseases or injuries, and as in vitro preclinical models for drug testing, differentiation and functional behavior of muscle cells within the microenvironment must be possible. One such strategy involves the application of miRNA delivery but reports to-date remain limited.
Recently, Cheng et al. [111] have been able to stimulate contraction of engineered 3D myobundles consisting of a fibrin hydrogel and human skeletal myoblasts (HSkM). The study examined the effects of siPORT NeoFxTM inhibition of miR133a and miR-696 on myogenic differentiation and function in 2D and 3D cultures of engineered myotubes when cultured under static conditions for 2 weeks. Overall, combined inhibition of miR-133a and miR-696 augmented differentiation, promoted expression of PGC-1a, and amplified the contractile force in 3D engineered myobundles validating 2D results.
Cardiovascular Tissue Repair
Repair of damaged myocardium for cardiovascular applications is limited due to the low proliferative rate of cardiomyocytes in adults [162] while insufficient angiogenesis has implications in vascular disease. Scaffold-based miRNA delivery for cardiovascular-related tissue has garnered a reasonable amount of interest in recent years as it can limit the risk of undesired offtarget miRNA effects on multiple mRNAs in several different tissues and is currently a growing area of research as documented here.
Zhou et al. [116] developed an electrospun fibrous membrane delivery system and target delivery carriers of miR-126 to vascular endothelial cells (VECs) in the local vascular environment. The scaffold consisted of a bilayer poly(ethylene glycol)-b-poly(llactide-co-e-caprolactone) (PELCL), PCL, and gelatin. The innermost layer of PELCL was loaded with complexes in REDV peptide-modified trimethyl chitosan-PEG and was responsible for regulating the response of VECs. Results showed that released miR-126 controlled VEC proliferation by down-regulation of SPRED-1 gene expression in vitro and improved endothelialization was found in vivo. Overall results suggest a useful platform for the localized delivery of miRNAs in vascular tissue engineering.
Tissue-engineered hydrogels have also been utilized in a study to enhance the direct reprogramming of fibroblasts into cardiomyocytes using miRNAs. [110] As direct reprogramming of cardiac fibroblasts in vitro is rather modest, a 3D hydrogel was used to enhance Dharmafect-miR combo (miR-1, miR-133, miR-208, miR-499) reprogramming of neonatal fibroblasts via a matrix metalloproteinase (MMP)-dependent mechanism in a more effective manner than 2D cell culture.
miR-29b has been the subject of a couple of papers related to wound healing and myocardial infarction. [108, 109] Firstly it was shown to ameliorate ECM remodeling when delivered from a collagen-based scaffold. Primary fibroblasts seeded on scaffolds loaded with naked miR-29b demonstrated reduced collagen type I and collagen type III mRNA expression of ≈40% and ≈15% respectively following 2 weeks of in vitro culture. The scaffolds were used to treat full thickness rat skin excisional wounds in vivo and showed reduced wound contraction, a 25% increase in granulation tissue, increased collagen type III/I ratios and improved MMP-8: tissue inhibitor of metalloproteinase (TIMP)-1 ratio when the scaffolds were functionalized with miR-29b in a dose-dependent manner (0.5 or 5 µg miR-29b). As myocardial infarction (MI) results in debilitating remodeling of the myocardial ECM, Monaghan et al. [109] performed a proof-of-principle study to modify aggressive myocardial remodeling by injecting a HyA-based hydrogel delivering exogenous miR-29b. Myocardial ischemia/reperfusion was performed on C57BL/6 mice for 45 min after the miRNA-activated hydrogel, composed of thiolated-HyA cross-linked with PEG-diacrylate (Glycosan HyStem) and naked exogenous miR29b, was injected into the border zone of the infarcted myocardium. This resulted in an ≈10% increase in ejection fraction, the maintenance of myocardial function following MI with significantly decreased elastin, newly deposited collagen fibers, increased vascularity of the myocardial scar and significantly altered ECM-specific biochemical signals found at the border zone of the infarct providing evidence for the use of injectable biomaterials and exogenous miRNAs as a local treatment for ischemic tissue to modulate tissue remodeling.
Another study undertook local lentiviral miRNA-26a delivery in a rat vein neointimal hyperplasia graft model. [114] MiR-26a has been shown to target MAPK6 to inhibit vascular smooth muscle cell (VSMC) proliferation making it a potential therapeutic target for autologous vein graft diseases. Vein segments were immersed in lentivirus solution (LV3-miR-26a or LV3-NC) and additional lentivirus solution was also preloaded into Pluronic F-127 gel and gently painted around the grafted vein segments. Delivery of LV3-miR-26a to the jugular vein inhibited graft-induced neointimal formation by up to 30%, resulted in decreases in the intima-to-media ratio and the number of MAPK6-expressing cells was also markedly decreased in the LV3-miR-26a-transduced jugular veins. Thus, this study underscores yet another therapeutic function for this popular miR26a in RM applications.
In a similar theme of research, miR-221 sponge therapy was utilized to attenuate neointimal hyperplasia and enhance vein graft blood flow. [163] ADVs encoding miR-221 sponge (Ad-miR-221-SP) were utilized to prevent VSMC proliferation in vitro and neointimal formation in vivo. The same F-127 pluronic gel was utilized to locally deliver Ad-miR-221-SP to the vein graft walls in a rat model. miR-221 sponge gene transfer reduced cell proliferation, neointimal area, thickness, and neointima/media ratio in vein grafts versus controls. Improved hemodynamics were detected in vein grafts and finally p27 (Kip1) was identified as a possible target gene of miR-221 in vein grafts. Overall results offer this miR-sponge therapy as a promising method to prevent vein graft failure.
Neurological Tissue Repair
To date, the strategies available for the treatment of majority of neurological pathologies remain suboptimal but scaffold-based miRNA delivery techniques offer new potential for the field of neural tissue engineering. Here, we document the reports available up to now in this research field.
The collective effects of scaffold topography and sustained gene silencing of miR-219 and miR-338 on oligodendroglial precursor cell (OPC) development have been assessed. [117] The miRNAs, complexed with TransIT-TKO, were integrated onto electrospun PCL fiber scaffolds with various fiber diameters and orientations. Efficient knockdown of differentiation inhibitory factors was achieved irrespective of fiber size or orientation. Overall the study presented a promising method for directing OPC maturation in neural tissue engineering and controlling remyelination in the central nervous system. The authors published a similar paper assessing the same miRNAs to enhance OPC differentiation and maturation. [139] Overall, the results of this study demonstrated the ability of PCL nanofibers to provide topographical cues and miRNA reverse transfection to direct OPC differentiation.
Recently, an aligned collagen-PCL-co-ethylethylene phosphate nanofibrous hydrogel scaffold has been utilized to nonvirally deliver miR-222-micellar NPs to direct axon regeneration in spinal cord injury treatment. [164] In vivo analysis was carried out on a rat spinal cord model to assess the efficacy of this hydrogel system. Results revealed aligned axon regeneration 1 week postinjury with no excessive inflammatory response or scar tissue formation. Results thus demonstrated the potential of this hydrogel system for neural tissue engineering applications.
Cui et al. [129] utilized a 3D collagen sponge-based scaffold to culture neural stem cells (NSCs) and PA-1 cells for different purposes. Though exogenous miRNA was not delivered on the scaffolds, 3D culture was utilized to demonstrate downregulation of several miRNAs, including miR-20, whose target genes are known to regulate self-renewal and differentiation of stem cells in 3D cultured PA-1 cells. NSC differentiation was also restricted in 3D scaffolds in comparison to 2D monolayer cell culture. Essentially, the study suggests 3D cell culturing might offer a system to demonstrate the regulatory mechanism of cell modulators, which are challenging to uncover in conventional 2D cell cultures. Mercado et al. [118] used a similar strategy using aminopropyl-silica nanofibers for the analysis of differentially expressed mRNAs and miRNAs of NSC differentiated on these nanofibers. The nanomaterial promoted the enhanced expression of let-7 miRNAs, which exhibit critical functions in NSC differentiation. Though these studies do not involve scaffold-based delivery of miRNAs, they highlight the utility of 3D scaffold-based systems for determination of more realistic responses compared to or in addition to 2D and point to a new line of research in the arena of neural tissue engineering.
Other Tissue Types: Cancer Treatments
While there is a large volume of research on the potential applications of miRNAs in cancer development and its treatment, it is clear that selective and targeted treatment to tumor cells alone needs increased research efforts. In direct and stark contrast to the typical systemic delivery of most conventional chemotherapeutic drugs, scaffold-based miRNA delivery systems surface as a highly appealing strategy. Furthermore, in recent years much interest has started to grow on the use of 3D scaffolds as a tool to study, in vitro, complex processes within a more in vivo representative microenvironment. This research avenue holds much potential to significantly improve the knowledge on targets of antitumoral treatments. As a result, there has been an increase of late on the development of safe, effective scaffoldbased miRNA delivery systems explored in several cancer types, in the form of both proof-of-concept and more complex detailed studies, as documented herein.
A dipeptide Gly-Ala linked with biphenyl-substituted tetrazole (Tet-GA) gel for 3D culture has been described for miR-122 mimic delivery into 3D HepG2 cultured cells as a proof-ofconcept study. [165] miR-122 is a liver-specific miRNA that is often reduced in hepatocellular carcinoma. Results indicated that the miRNAs were able to inhibit target gene expression demonstrating the first indication of 3D miRNA delivery into live cells facilitated by a Tet-GA gel. Work performed more recently by the same group focused on the use of a supramolecular hydrogel formed by spiropyran conjugated galactose (MCI-Gal gel) for photocontrolled release of miR-122 mimic and target-mediated delivery of the miRNA into the same HepG2 cells cultured on the gel. [166] Visible light irradiation was used to accelerate the release of the encapsulated miRNA while the incorporation of galactose targeting ligand was able to improve the miRNA delivery efficiency through ligand-receptor interaction. Encapsulation of miRNA in the gel matrix was proven to have no adverse effect on the biological function of the miRNA. This supramolecular hydrogel therefore provides a possibility of investigating miRNA function in targeted cell lines using a spatiotemporal approach.
Conversely, Beavers et al. [167] described a novel system for the delivery of an inhibitor of miR-122. The authors described a porous silicon and polymer nanocomposite (PSNP) system for delivery of PNAs as anti-miRNA therapies describing it as the first example of an endosomolytic PNA delivery platform and of in vivo PNA-mediated miR-122 inhibition. PNAntimiR-122-loaded PSNPs were injected intravenously into mouse tail veins. Results showed 46% miR-122 inhibition, equating to 16 times lower than that reported previously for RNAntagomiR-122, [26] and 2.5 times lower than 2-O-methoxyethyl phosphorothioate antisense oligos. Efficacy of this inhibition further resulted in 1.5-fold increase in mRNA levels of validated downstream targets and ultimately provoked a beneficial 20% reduction in HDL-cholesterol. [168] This study overcomes both the crucial systemic and intracellular delivery obstacles facing PNA by development of the strategic nanocomposite.
miR-34a, a known tumor suppressor gene, has also been a miRNA of interest in a few scaffold-based cancer-related miRNA delivery studies. [169, 170] PCL scaffolds containing miR34a mimics were fabricated as a "neutral-lipid-emulsion" delivery system and then implanted in the flank of severe combined immunodeficiency (SCID) mice. [169] In vivo results corroborated in vitro experiments where miR-34a mimics confirmed significant anti-proliferative effects, apoptotic activity and control of gene expression, thus proving evidence of the antitumoral activity of miR-34a in preclinical scaffold systems of this disease. Zhou et al. [170] have most recently described a proof-of-concept study outlining a multifunctional supramolecular hydrogel formed by the conjugate of the peptic sequence GRGDS with biaryltetrazole (Tet(II)-GRGDS) for the delivery of miR-34a into encapsulated U87 cells, a human primary glioblastoma cell line. The presence of biaryltetrazolein in the hydrogel results in a sensitive photo-response reaction which allowed photodegradation of the hydrogel for release of the encapsulated live cells. U87 cells were firstly cotransfected with Luc-miR-34a plasmid and β-galactosidase plasmid using Lipofectamine2000 before being mixed with the hydrogel. Functionality results showed a significant decrease of ≈80% of luciferase signals in U87 cells encapsulated in the Tet(II)-GRGDS gel indicating its potential as a 3D carrier. Shatsberg et al. [171] have also utilized delivery of miR-34a as a replacement therapy in a proof-of-concept study, delivered by 6 different polymeric nanogels (NGs), which are based on a polyglycerol-scaffold, with the view to inhibition of glioblastoma via downregulation of miR34a target oncogenes. U87 cells, as used in the previous study, were transfected with NG-miR-34a nanopolyplexes and resulted in significant downregulation of miR-34a target genes, while treatment of SCID mice with intratumoral injection of human U87s expressing NG-miR-34a showed dramatic knockdown of tumor growth. The study outlined the vital characteristics for the coherent design of polymeric delivery systems for oligonucleotides and this novel therapeutic method may lead the path for safe, efficient therapies for glioblastoma.
Conde et al. [78] have described a recent study describing the use of a self-assembled RNA-triple-helix structure containing two miRNAs, a miR-205 mimic and antagomiR-221, that synergistically abrogate tumors in a triple-negative breast cancer mouse model (Figure 6) . The RNA triplex NPs were combined with PAMAM dendrimers and dextran aldehyde to form a dextran-dendrimer-RNA triplex hydrogel that strongly adheres to tumor tissue. For in vivo assessment, hydrogel scaffolds were loaded with the miRNAs or drugs (doxorubicin, paclitaxel, and the monoclonal antibody bevacizumab (Avastin)
Adv. Healthcare Mater. 2018, 7, 1700695 Figure 6 . In vivo miRNA modulation and tumor therapy via PAMAM RNA-triple-helix dextran-based hydrogel scaffolds. a) Single or dual-colored miR-nanoconjugates forming the RNA-triple-helix nanoparticles within the hydrogel scaffolds demonstrate homogenous distribution throughout its structure. b) 12 µm cryosection of RNA-triple-helix hydrogel depicting dextran presence (Alexa Fluor 405) and with nanoparticles containing the dual-colored miRs shown as red spots. c) Presence of the RNA-triple-helix nanoparticles embedded in dextran hydrogels is detected via fluorescence live imaging when implanted in female SCID mice with triple-negative breast tumor xenograft, n = 5. Adapted with permission. [78] Copyright 2016, Macmillan Publisher Ltd. and implanted for 13 d next to the tumor in the mammary fat pad of SCID mice. Only the RNA-triple-helix hydrogel scaffolds (carrying miR-205 mimic and antagomiR-221) resulted in efficient, sustained inhibition of tumor progression, with ≈90% tumor size reduction. The findings suggested that this may be an effective anticancer platform for local control endogenous miRNA expression in cancer. Many of the same authors were also involved in another study involving local miR-96 or miR-182 treatment for targeting Palladin, a gene involved in the invasive behavior of breast cancer cells, thereby preventing metastatic breast cancer. [172] An oxidized AuNP-dextran-dendrimer based hydrogel system was used to provide an effective local, selective, and sustained release of miR-96/miR-182, and demonstrated prominent suppression of metastasis in a mouse breast cancer model. By combining the codelivery of miRNAs with the chemotherapy drug, cisplatin, significant primary tumor reduction and metastasis inhibition were obtained. This combined therapy (involving cisplatin and miRNAs) thus suggests a plausible reason for the inclusion of miRNA therapy as an additive to conventional chemotherapy.
Conclusion and Future Outlook
As the immense potential of miRNA therapeutics has exploded, scaffold-mediated miRNA-based delivery systems have garnered significant attention in recent years. miRNA therapeutics have been widely explored for cancer treatment and genetic disorders, although their use in RM has somewhat lagged behind. To date, much of the research has focused on miRNA profiling and elucidating miRNA involvement in signaling pathways but slowly this work has begun to inspire RM applications as we have described herein. Unfortunately however, there is currently no real consensus on which direction is best for the field to proceed as it is still laying its foundations. As can be deduced from Table 2 , the nature of scaffolds used is highly variable, vector type in terms of RM although variable has had the most reports using lentivirus or baculovirus and the cells types most commonly assessed include BM-MSCs and ASCs. In terms of miRNA targets, some leaders have emerged depending on the application being assessed; miR-26a, miR-31, and miR-148b have set the precedent for the osteogenesis and bone repair field, miR-29b for the cardiovascular field while miR-122 and miR-34a are the current frontrunners when it comes to miRNA scaffold-based therapies for cancer treatment. A number of challenges still need to be fully addressed and resolved however before the true potential of miRNA scaffold-based therapies is realized including development of the most efficient scaffold-vector delivery system, biological stability, precise targeting capacity and prolonged but transient presentation in addition to limitation of offtarget effects. Despite the challenges identified with miRNA therapeutics, companies like Santaris Pharma, Regulus Therapeutics, MiRagen Therapeutics, and EnGeneIC have recently embarked in clinical trials, taking up the challenge to translate miRNA therapies to patient benefit. From these early stage trials it appears that a new era of clinical translation is on the horizon, with the focus on the application of miRNA-based medicine looming to go beyond cancer therapies. In particular, personalized medicine, based on the patient's personal miRNA signature, may be one area where precise tailoring of scaffoldmediated miRNA therapies can be exploited. To date, the field of scaffold-mediated RNA delivery resides at a relatively nascent juncture; however, the bulk of reports on siRNA delivery provide valuable strategies thought to accommodate miRNA therapeutics almost seamlessly. Ultimately, the development of efficient and effective scaffold-based miRNA therapies would appear to offer significant promise though much work still needs to be completed from a regulatory perspective. In conclusion, we believe scaffold-mediated miRNA delivery will play a vital role in the future of RM and cancer therapy. With the constant evolution and rapid identification of new targets on an almost daily basis, we envisage a spate of new strategies will drive this field to even further, exciting new levels in the coming years.
